The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression

Clinical Psychopharmacology and Neuroscience

Volumn 12, Issue 1, 2014, Pages 72-73

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; ESKETAMINE; KETAMINE; MIDAZOLAM;

ANTIDEPRESSANT ACTIVITY; HUMAN; LETTER; MAJOR DEPRESSION; METABOLIC RATE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEREOISOMERISM; TREATMENT OUTCOME;

EID: 84899508429     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2014.12.1.72     Document Type: Letter

References (7)

1. Hashimoto K. Therapeutic implications for NMDA receptors in mood disorders. Expert Rev Neurother 2013;13:735-737.
2. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013;73:1133-1141.
3. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170:1134-1142.
4. Rush AJ. Ketamine for treatment-resistant depression: ready or not for clinical use? Am J Psychiatry 2013;170:1079-1081.
5. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010;113:678-684.
6. Zhang JC, Li SX, Hashimoto K. R (-)-Ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 2014;116:137-141.
7. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997;7:25-38.